FDA-Approved Device Positions Company in High-Value Neurorehabilitation Segment

Mobia Medical has filed with the SEC to raise up to $100 million in an initial public offering, as the company looks to scale commercialization of its FDA-approved neurostimulation therapy for stroke recovery. The Austin-based firm plans to list under the ticker MOBI, though pricing terms have not yet been disclosed.

The IPO filing comes as investor interest in medical technology and neurorehabilitation solutions continues to build, particularly in areas with large underserved patient populations.

Proprietary Device Targets Chronic Stroke Recovery

Mobia’s core product, the Vivistim Paired Vagus Nerve Stimulation System, is positioned as a differentiated solution in stroke rehabilitation. The system combines an implantable pulse generator and lead with therapy-driven stimulation designed to enhance neuroplasticity, enabling patients to regain motor function over time.

Notably, the therapy is described as the first and only clinically validated, FDA-approved treatment for chronic ischemic stroke patients with moderate to severe upper limb impairments, placing it in a unique regulatory and clinical position.

Large Addressable Market Supports Growth Narrative

Management estimates that more than four million chronic ischemic stroke survivors exist, with approximately one million patients considered suitable candidates for this type of therapy. Based on system pricing, the company sees a total addressable market of roughly $30 billion, highlighting significant long-term growth potential.

This market sizing reflects both the high cost of advanced medical devices and the ongoing demand for effective rehabilitation solutions in aging populations.

Financial Profile Reflects Early Commercial Stage

For the 12 months ended December 31, 2025, Mobia Medical reported $32 million in revenue, indicating that the company is still in the early stages of scaling its commercial footprint. Like many medtech firms at this stage, the focus remains on adoption rates, clinical expansion, and reimbursement pathways, rather than immediate profitability.

The IPO proceeds are expected to support broader commercialization, clinical data expansion, and operational scaling.

Strong Syndicate Signals Institutional Interest

The offering is backed by a major underwriting group including BofA Securities, J.P. Morgan, and Goldman Sachs, suggesting a high level of institutional engagement. Such syndicates are typically associated with deals that have strong growth narratives and differentiated technology platforms.

The absence of pricing details indicates that the company is still in early stages of the IPO process, with valuation likely to be determined closer to launch based on market conditions.

Outlook

Mobia Medical’s IPO filing underscores increasing investor focus on innovative healthcare technologies that address large, unmet medical needs. Its combination of regulatory approval, clinical validation, and sizable market opportunity positions the company within a compelling segment of the medtech landscape.

Future performance will depend on therapy adoption, reimbursement expansion, and continued clinical validation, all of which will play a central role in determining whether the company can translate its technology into sustained revenue growth.